Core Viewpoint - David Medical (300314.SZ) has received the Medical Device Registration Certificate from the Zhejiang Provincial Drug Administration for its new product, the electric surgical table [1] Group 1 - The electric surgical table is a new product developed by the company [1] - The approval from the Zhejiang Provincial Drug Administration signifies a regulatory milestone for the company [1]

Group 1 - The core point of the article is that David Medical (300314.SZ) has received the Medical Device Registration Certificate from the Zhejiang Provincial Medical Products Administration for its new product, the electric surgical table [1] Group 2 - The electric surgical table is a new product introduced by the company, indicating a potential expansion in its product line [1] - The approval from the regulatory authority suggests that the product meets the necessary safety and efficacy standards required for medical devices [1] - This development may enhance the company's market position and competitiveness in the medical equipment industry [1]

产品名称：电动手术台 型号、规格：DT-100/DT-100A/DT-100B/DT-100C/DT-100D 注册证编号：浙械注准20252151942 证券代码：300314 证券简称：戴维医疗 公告编号：2025-087 宁波戴维医疗器械股份有限公司 关于新产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，宁波戴维医疗器械股份有限公司（以下简称"公司"）的新产 品电动手术台获得了浙江省药品监督管理局颁发的《医疗器械注册证》， 具体如下： 一、医疗器械注册证的具体情况 在任何体位下都具有高承重的功能，能够满足手术的多变性和患者的不同 体位。模块化设计的台面更能适用于多种多样的手术，简单的按钮式连接 关节使其操作更加简便。 三、对公司的影响 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提 高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 批准日期：2025年12月8日 有效期至：2030年12月7日 注册分类：Ⅱ类 适用范围：本设备用于常规手术、神经外科、胸腹外科、骨科、泌尿 外科肛肠科、整形外科、妇科 ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Devices Co., Ltd. (referred to as "Weierkaidi"), has recently received two Medical Device Registration Certificates from the Zhejiang Provincial Drug Administration [1] Group 1 - The two registered medical devices are: 1) disposable gastric tubes, and 2) disposable electronic ureteral renal pelvis endoscope catheters [1]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd. (referred to as "Weierkaidi"), has recently received two Medical Device Registration Certificates from the Zhejiang Provincial Drug Administration for products including disposable gastric tubes and disposable electronic ureteral renal pelvis endoscope catheters [1] Group 1 - The company has received regulatory approval for two new medical devices [1] - The approved products are disposable gastric tubes and disposable electronic ureteral renal pelvis endoscope catheters [1]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd. (referred to as "Weierkaidi"), has recently received two Medical Device Registration Certificates from the Zhejiang Provincial Drug Administration for products including disposable gastric tubes and disposable electronic ureteral renal pelvis endoscope catheters [1] Group 1 - The company has received regulatory approval for two new medical devices [1] - The approved products are disposable gastric tubes and disposable electronic ureteral renal pelvis endoscope catheters [1]

Group 1 - The core point of the article is that David Medical (300314) announced that its wholly-owned subsidiary, Weierkaidi, has received two medical device registration certificates from the Zhejiang Provincial Drug Administration for specific products [1] Group 2 - The registered products include disposable gastric tubes and disposable electronic ureteral renal pelvis endoscopic catheters [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-086 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 注册分类：Ⅱ类 适用范围：适用于插入胃部，排空、清洗、灌注用。 2、一次性使用电子输尿管肾盂内窥镜导管 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日收到浙江 省药品监督管理局颁发的2项《医疗器械注册证》，具体如下： 一、医疗器械注册证的具体情况 1、一次性使用胃管 型号、规格：GCT-A-34F、GCT-A-36F、GCT-A-38F、GCT-A-40F、GCT-B-34F、 GCT-B-36F、GCT-B-38F、GCT-B-40F 注册证编号：浙械注准20252141946 批准日期：2025年12月8日 有效期至：2030年12月7日 型号、规格：DW-U-25、DW-U-29 注册证编号：浙械注准20252061948 批准日期：2025年12月8日 有效期至：2030年12月7日 注册分 ...

格隆汇12月8日丨戴维医疗(300314.SZ)公布，全资子公司宁波维尔凯迪医疗器械有限公司于近日取得由 浙江省药品监督管理局颁发的《中华人民共和国医疗器械变更注册（备案）文件》，公司产品一次性使 用腔镜用直线型切割吻合器组件完成了医疗器械产品注册变更。 ...